


I - Princípio de Transfecção Celular



(f = células)

{ - hormonas
- Fatores de ↑

3
K
E
P
R
O
G
R
A
M.

2
- f adultas

- f embriões

- f sources adultas.


- f pluripotentes induzidas

1
autóloga
- fêmea

vs.

allogênica


II - Rise in volume & Limits





mais effet > 0

- ?
- ~~effet mécanique~~
 - stim. Répar.?
 - effet hormones locales

III - Jcs Cellulaire (12/2023)



4 sang



- i.c. stabil.

- 0 effet second



immun. ?



rate


(E.C. = essai clinique)

- E.C. SECRET-HF
- 3 patients.
- 1 patient: 2x

- 30 min.
- 3 x, 3 sem.
- 60. 10⁴ part. / Kg.


II - Patches & Organoids

- 4 Sources
- 2D patches
- 3D organoids




filaments

- Fibrine
- nanofibers biodegradable (peptides)
- nanofibers silicon (conduct.)



- Contract. $\nearrow$
- $\uparrow$ Vascul.
- 4 $\searrow$
- animals.


V - C Souches autologues



- EC. EXCELLENT
- CHO Nancy.
- 10ans
- 300 patients

- 6 mois:
- ↑ Fonction syst.
 - ↓ marqueurs cytolys.
 - ↑ cicatrice
 - neovascul.

VI - AVC



modalités

- timing?
- kb 4?
- compatib.
- voie


mécanismes

- neurones AT
- $\rightarrow$ apoptose
- $\rightarrow$ inflamm.
- $\uparrow$ O_2 fact. vascul.

Sept 2024

- E.C. RESSTORE
- CHU Grenoble
- 3 centres
- 80 $\rightarrow$ 400 patients
- 4 tumeurs adipeuses (liposuccion)
- i.v.
- 2 ans
- Résu. 2026

VII - Cœur Artificiel



- E.C. ① 2013 - 2015
- 4 patients
- fuites, arrêts.
- complications

- E.C. ② 2013
- 20-25 patients
- erreur manip. batt.
- Arrêt E.C. Nov. 2016

assist.
Externe

- E.C. Tchèque, Kazakhstan...
- USA.
- ANSM 2017
- marquage CE 2020
- talie 2021 (AFSDN)
- PD qualit. 2021 - 2022

- FR E.C. EFICAS 2022
- 10 centres, 52 patients
- 200 000 €
- Dijon juin 2023
- 100th Fév. 2025